Showing 1 - 3 results of 3 for search 'H. Keer', query time: 0.02s Refine Results
  1. 1
    PHASE 3B STUDY DESIGN: COMPARING TREATMENT PREFERENCE BETWEEN ORAL DECITABINE/CEDAZURIDINE AND AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME, LOW-BLAST ACUTE MYELOID LEUKAEMIA, OR CHRONIC MYELOMONOCYTIC LEUKAEMIA

    PHASE 3B STUDY DESIGN: COMPARING TREATMENT PREFERENCE BETWEEN ORAL DECITABINE/CEDAZURIDINE AND AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME, LOW-BLAST ACUTE MYELOID LEUKAE... by A. Enjeti, C. Fong, T. Paine, F. Castaldi, G. Van Wyk, R. Walton, H. Keer

    Published 2024-01-01
    Get full text
    Article
  2. 2
    P768: GUADECITABINE (SGI-110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY.

    P768: GUADECITABINE (SGI-110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY. by G. Garcia-Manero, S. Bart, J. K. McCloskey, P. Fenaux, D. Selleslag, G. Reda, D. Valcárcel, V. Santini, J. Mayer, B. Xicoy, H. Yamaguchi, M. Lübbert, Y. Miyazaki, H. Keer, Y. Hao, M. Azab, H. Döhner

    Published 2022-06-01
    Get full text
    Article
  3. 3
    P573: PHARMACOKINETIC EXPOSURE EQUIVALENCE AND PRELIMINARY EFFICACY AND SAFETY FROM A RANDOMIZED CROSS OVER PHASE 3 STUDY OF AN ORAL HYPOMETHYLATING AGENT DEC-C COMPARED TO IV DECITABINE IN AML PATIENTS

    P573: PHARMACOKINETIC EXPOSURE EQUIVALENCE AND PRELIMINARY EFFICACY AND SAFETY FROM A RANDOMIZED CROSS OVER PHASE 3 STUDY OF AN ORAL HYPOMETHYLATING AGENT DEC-C COMPARED TO IV DECI... by K. Geissler, Z. Koristek, T. Bernal del Castillo, J. Novák, G. Rodriguez Macias, S. K. Metzelder, A. Illes, A. Nagy, J. Mayer, M. Arnan, M.-M. Keating, J. Krauter, M. Lunghi, N. Stefano Fracchiolla, U. Platzbecker, V. Santini, Y. Sano, A. Oganesian, H. Keer, M. Lübbert

    Published 2022-06-01
    Get full text
    Article

Search Tools: